For how we live.
ACHIEVE-4 found the non-peptide GLP-1 pill non-inferior to insulin glargine for major cardiac events over two years, with less severe hypoglycaemia but far more gastrointestinal upset. Lilly funded it.
Pooling 2,906 participants, researchers ranked how antidiabetic drugs affect fat versus lean body mass. Exercise blunted liraglutide's muscle loss; metformin, insulin, and DPP4 inhibitors barely moved either measure.
SURPASS-CN-INS randomised 257 adults at 26 Chinese hospitals. The 10 mg and 15 mg doses performed almost identically against placebo, and diarrhoea affected roughly a third of those on the higher doses.